AbbVie has revealed the Phase II study results of the investigational medicine veliparib in patients with non-small cell lung cancer (NSCLC).

The veliparib combined with the chemotherapy regimen carboplatin and paclitaxel demonstrated an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced NSCLC who are current smokers.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Veliparib is an investigational oral poly is an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, which is being assessed to treat various cancer types, including NSCLC.

AbbVie oncology clinical development vice president Dr Gary Gordon said: "The results from this study reinforce AbbVie’s continued investigation of veliparib in treating advanced non-small cell lung cancer, including patients with a history of smoking."

The Phase II trial assessed survival outcomes in previously untreated metastatic or advanced NSCLC patients treated with either a regimen consisting of a carboplatin, paclitaxel (C/P) or carboplatin, paclitaxel combined with veliparib (V+C/P).

The study also evaluated patients based on their smoking status and each experimental arm of the 158 patient study comprised current smokers, former smokers and non-smoker subgroups.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the firm, current smokers treated with V+C/P had a median PFS of 5.6 months compared against 3.3 months for patients treated with C/P alone and non-smokers treated with V+C/P had a median PFS of 6.4 months compared to 5.6 months in patients treated with C/P alone.

In addition, current smokers treated with V+C/P had a median overall survival of 12.5 months compared to 5.4 months for patients treated with C/P alone and former smokers treated with V+C/P had a median overall survival of 8.6 months compared to 14.67 months with those treated with C/P alone, the company said.